Rash News and Research

RSS

New legislation allows physicians in Texas to treat chronic Lyme disease

Summertime, when kids and grown-ups abandon the confines of the indoors and head outside to camp, hike, fish and commune with nature -- and all of her friends. Flies, mosquitoes and ticks are just a few of the critters that go along with summer outdoors, and we all do our best to avoid the biting and stinging insects, but what happens if you are accosted by a tick? What are the myths behind Lyme disease and other tick-borne diseases in Texas?.

5 Aug 2011

Tips to minimize risk of bug bites and related illnesses

While the image of a bug crawling on your arm or a creepy crawler snuggling up in your bed is enough to make you flinch, most bug bites are harmless and disappear on their own in a matter of days. Other insects, however, can spread disease and cause severe reactions that require medical attention.

4 Aug 2011

Instituto Bioclon receives FDA approval for Anascorp to treat Centruroides scorpion sting

The U.S. Food and Drug Administration today approved Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the United States.

4 Aug 2011

Fluoride supplements neither safe or effective

Sodium fluoride supplements "have not been found by FDA to be safe or effective," according to the U.S. National Library of Medicine's website, reports the New York State Coalition Opposed to Fluoridation, Inc..

25 Jul 2011

Bristol-Myers Squibb announces results of BMS-708163 Phase II study on Alzheimer's

Bristol-Myers Squibb Company today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer's disease.

21 Jul 2011

Promising results from phase I study of Genentech's GDC-0941 for advanced breast cancer

A new drug targeting the PI3K gene in patients with advanced breast cancer shows promising results in an early phase I investigational study conducted at Virginia G. Piper Cancer at Scottsdale Healthcare, according to a presentation by oncologist Dr. Daniel D. Von Hoff at the 47th annual meeting of the American Society of Clinical Oncology.

21 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Measles epidemic grips Kenya and Ethiopia

The UNICEF announced Friday that children in Kenya and Ethiopia are at risk of a measles epidemic. Ethiopia has had more than 17,584 cases of measles in 2011, with 114 deaths. The WHO urges measles vaccination of young children to combat the situation.

18 Jul 2011

Zocor, Crestor drugs may cause serious muscle and kidney problems

Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase.

16 Jul 2011

Berks County's Department of Health advises public about possible measles exposure

The state Department of Health is advising the public of a possible case of measles exposure in Morgantown, Berks County.

15 Jul 2011

Positive top-line results from alemtuzumab Phase 3 trial on multiple sclerosis

Sanofi and its subsidiary Genzyme announced today positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif in patients with relapsing-remitting multiple sclerosis.

11 Jul 2011

PEP intervention increases breast cancer awareness

Educating women about breast cancer increases their knowledge about the disease should they develop a symptom - and could help increase survival from breast cancer, new research today shows.

29 Jun 2011

Macrogenics' Protege Phase 3 clinical study of teplizumab in type 1 diabetes published in The Lancet

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, announced the publication in The Lancet of results from Protege, a Phase 3 clinical study of teplizumab in type 1 diabetes.

29 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Positive results from etanercept pilot study against dermatomyositis

A multicenter pilot study of etanercept for treatment of dermatomyositis found no major safety concerns and many patients treated with the drug were successfully weaned from steroid therapy.

17 Jun 2011

Untreated obstructive sleep apnea can reduce work productivity

Large corporations could save millions of dollars in lost productivity by screening and treating high-risk employees for obstructive sleep apnea, suggests a research abstract that will be presented Monday, June 13, in Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting of the Associated Professional Sleep Societies LLC.

14 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

10 Jun 2011

New NCIN report: Poorer women more likely to die from breast cancer

Poorer women from deprived areas are less likely to survive breast cancer as they are diagnosed at a later stage which means the best available treatments won't be as effective according to a new report out today (Thursday) by the National Cancer Intelligence Network (NCIN).

9 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011